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WHAT IS ALREADY KNOWN ABOUT
THIS SUBJECT
• The pharmacokinetics of cyclophosphamide and
4-hydroxycyclophosphamide in cancer patients have
been well described. The current study was
conducted to document the pharmacokinetics of
cyclophosphamide and
4-hydroxycyclophosphamide in patients with
glomerulonephritis. The study was necessary due to
the numerous clinical abnormalities that are present
in glomerulonephritis (altered glomerular filtration
rate, proteinuria, hypoalbuminaemia) which can alter
the disposition of drugs.
WHAT THIS STUDY ADDS
• This study documents the differences in
pharmacokinetics of cyclophosphamide and
4-hydroxycyclophosphamide in glomerulonephritis
vs. the cancer population. The current results
demonstrate that clinical and pharmacogenetic




Cyclophosphamide, the precursor to the active 4-hydroxycyclophosphamide, is used in active
glomerulonephritis despite limited pharmacokinetics data. The pharmacokinetics of cyclophosphamide
and 4-hydroxycyclophosphamide were evaluated. The influence of laboratory and pharmacogenomic
covariates on pharmacokinetics was evaluated as a secondary aim.
METHODS
Glomerulonephritis patients (n = 23) participated in a pharmacokinetic evaluation. Blood was serially
collected and assayed for cyclophosphamide and 4-hydroxycyclophosphamide by LC/MS methods. Kidney
function, serum albumin and polymorphisms in drug metabolism or transport genes were evaluated.
Analyses included non-compartmental pharmacokinetics and parametric and non-parametric statistics.
RESULTS
The mean area under the plasma concentration–time curve (AUC(0,•)) data were 110 100  42 900 ng ml-1 h
and 5388  2841 ng ml-1 h for cyclophosphamide and 4-hydroxycyclophosphamide, respectively.The mean
metabolic ratio was 0.06  0.04. A statistically significant relationship was found between increased serum
albumin and increased half-life (0.584, P = 0.007, 95% CI 0.176, 0.820) and a borderline relationship with AUC(0,•)
(0.402, P = 0.079, 95% CI –0.064, 0.724) for 4-hydroxycyclophosphamide. Covariate relationships that trended
toward significance for cyclophosphamide included decreased serum albumin and increased elimination rate
constant (–0.427, P = 0.061, 95% CI 0.738, 0.034), increased urinary protein excretion and increased AUC(0,•)
(–0.392, P = 0.064, 95% CI –0.699 to 0.037), decreased Cmax (0.367, P = 0.085, 95% CI –0.067, 0.684) and decreased
plasma clearance (–0.392, P = 0.064, 95% CI –0.699, 0.037). CYP2B6*9 variants vs. wildtype were found to have
decreased elimination rate constant (P = 0.0005, 95% CI 0.033, 0.103), increased Vd (P = 0.0271, 95% CI -57.5,
-4.2) and decreased Cmax (P = 0.0176, 95% CI 0.696, 6179) for cyclophosphamide. ABCB1 C3435T variants had a
borderline decrease in cyclophosphamide elimination rate constant (P = 0.0858; 95% CI –0.005, 0.102).
CONCLUSIONS
Pharmacokinetics of cyclophosphamide and 4-hydroxycyclophosphamide in patients with lupus nephritis
and small vessel vasculitis are similar. Clinical and pharmacogenetic covariates alter disposition of
cyclophosphamide and 4-hydroxycyclophosphamide. Clinical findings of worsened glomerulonephritis
lead to increased exposure to cyclophosphamide vs. the active 4-hydroxycyclophosphamide, which could
have relevance in terms of clinical efficacy. The CYP2B6*9 and ABCB1 C3435T polymorphisms alter the
pharmacokinetics of cyclophosphamide and 4-hydroxycyclophosphamide in glomerulonephritis.
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Introduction
Cyclophosphamide is an alkylating agent used in the treat-
ment of breast, ovarian and lung carcinomas and to treat
glomerulonephritides resulting from systemic lupus
erythematosus (SLE) and small vessel vasculits (SVV) [1–5].
The later application is off-label use in the USA. Cyclophos-
phamide undergoes biotransformation by cytochrome
P450 (CYP450) enzymes to a series of metabolites includ-
ing the important pharmacologically active moiety,
4-hydroxycyclophosphamide [6–8]. The CYP450s CYP2B6,
CYP2C9, CYP3A4 and, possibly, CYP2C9 are relevant in
the formation of 4-hydroxycyclophosphamide from cyclo-
phosphamide. 4-hydroxycyclophosphamide undergoes a
spontaneous reaction to the phosphoramide mustard
[N,N-bis-2-(2-chloroethyl) phosphorodiamidic acid] to
alkylate guanidine residues in DNA [9, 10].
The pharmacokinetics of cyclophosphamide and
4-hydroxycyclophosphamide are important determinants of
therapeutic responses in the treatments of various cancers,
with greater exposure to 4-hydroxycyclophosphamide
leading to better outcomes but with increased toxicity
risks [11, 12]. In patients with glomerulonephritis, cyclo-
phosphamide treatment-related outcomes are highly
variable. This could be due to factors that may alter expo-
sure to 4-hydroxycyclophosphamide including patient
genetic background, drug interactions or physiologic
changes related to nephritis, e.g. urinary protein excretion
and/or decreased serum albumin. Inferior efficacy to
cyclophosphamide-based treatments based on race has
been reported in steroid resistant nephrotic syndrome and
SLE nephritis [13–16]. The metabolism of cyclophospha-
mide can be altered based on concomitant medications.
Induction can occur with glucocorticoids, ondansetron,
rifampicin and phenobarbital and autoinduction can
occur with cyclophosphamide itself [17–19]. However,
induction of metabolism may be beneficial secondary
to increased formation of 4-hydroxycyclophosphamide.
Finally, glomerulonephritis-associated changes in
kidney function and plasma proteins may alter the
disposition of cyclophosphamide and exposure to 4-
hydroxycyclophosphamide.
Since cyclophosphamide treatment-related outcomes
are variable in patients with glomerulonephritis, studies
to evaluate its pharmacokinetics are urgently needed.
These studies lay the groundwork for subsequent assess-
ments of the relationship between pharmacokinetics
and outcomes and ultimately towards development
of clinical guidelines defining exposure targets for 4-
hydroxycyclophosphamide. The primary objective of
this study was to describe the pharmacokinetics of
cyclophosphamide and 4-hydroxycyclophosphamide in
patients with glomerulonephritis secondary to SLE nephri-
tis and SVV. Secondary objectives were to explore the
influence of covariates of race, gender, concomitant
medications, genetic variability and clinical parameters




Patients with biopsy confirmed SLE or SVV nephritis and
prescribed monthly intravenous cyclophosphamide were
evaluated for enrolment. Female patients were required to
have a negative urine pregnancy test. All patients were
required to have an absolute neutrophil count of
>3.0 ¥ 109 l-1 and haemoglobin of at least 10 mg dl–1. Con-
comitant therapy with other medications was allowed and
recorded.
Enrolled subjects were admitted to the General Clinical
Research Unit (GCRC) to participate in a 24 h pharmacoki-
netic analysis of cyclophosphamide and 4-hydroxycy-
clophosphamide. Patients were fasting at study initiation
and fed a special diet throughout the study. The diet
avoided food items including cruciferous vegetables,
spinach, garlic, grapefruit, char-grilled meats, and smoked
meats that can influence the activity of CYP450 drug
metabolizing enzymes [20]. Clinical parameters measured
or calculated at the time of the study were serum creati-
nine, estimated creatinine clearance (eCLcr), urinary protein
to creatinine excretion ratio (UP : Cr) and serum albumin
[21]. The study and consent form were approved by the
Biomedical Institutional Review Board.
Pharmacokinetic study
Blood samples for cyclophosphamide and 4-
hydroxycyclophosphamide determination were collected
at the beginning of the infusion and at 0.5, 1, 2, 3, 4, 6, 8, 12,
18 and 24 h after commencement. The collection tubes
were prepared by filling 7.0 ml EDTA blood tubes with 4 ml
of a derivatizing agent, phenylhydrazine hydrochloride
(Fisher Scientific, Pittsburgh, PA). Briefly, bulk phenylhydra-
zine solution was prepared as 4.0% (w/v) phenylhydrazine
hydrochloride in 0.1 M sodium citrate buffer adjusted to
pH 6.0 with 0.5 M NaOH. Aliquots (4 ml) were transferred
to lightly capped 7.0 ml plastic vacutainer tubes and
placed in a vacuum chamber (20 inches (50.8 cm) Hg for
5–12 min).The tubes were stored at -80°C until thawed for
use. During the pharmacokinetic study, 3 ml of whole
blood was collected into the prepared vacutainer tubes,
inverted to complete mixing, kept on ice at 4°C and centri-
fuged at 3000 rev min–1 (2100 g) for 5 min (Beckman CS-6R
centrifuge).
Chemicals and reagents
Chemicals including methanol, acetonitrile, glacial acetic
acid, sodium hydroxide, sodium citrate and cyclophospha-
mide were obtained from Fisher Scientific (Pittsburgh, PA).
The 4-hydroperoxycyclophosphamide and d4-cyclophos-
phamide were obtained from NIOMECH at the Institute for
M. S. Joy et al.
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Innovation Transfer at the University of Bielefeld (Bielefeld,
Germany). p-chlorowarfarin (Coumachlor) was purchased
from Sigma-Aldrich (St Louis, MO).
Sample processing and assays
4-hydroxycyclophosphamide The sample processing and
assay procedures for 4-hydroxycyclophosphamide were
modified from a previously published method [22]. To
start, 1 ml of sample was centrifuged and extracted using
Bond Elute SPE columns (C-18, 200 mg, Varian, Lake Forest,
CA). Next, 10 ml of the internal standard, p-chlorowarfarin
(20 mM) and 175 ml of eluate were transfered to HPLC-
autosampler vials. All processed samples were analyzed
immediately.
Sample analysis involved a Shimadzu solvent delivery
system (Columbia, MD) and a Leap HTC Pal autosampler
(Carrboro, NC) connected to an Applied Biosystems API
3000 triple quadrupole mass spectrometer (Foster City, CA)
with a TurboIonSpray source. Tuning, operation, peak inte-
gration and data analysis were performed in negative ion
mode using multiple reaction monitoring (Analyst soft-
ware v.1.4.1, Applied Biosystems). Reverse phase separa-
tion (aqueous phase was 1.0 mM ammonium chloride,
10 mM ammonium acetate, pH 8.5 and organic mobile
phase was 100% methanol) was accomplished using a
Synergi Max-RP 30 ¥ 2 mm column with a 4 m particle size
(Phenomenex, Torrence, CA). Analysis required a 5 ml injec-
tion and a solvent flow of 0.75 ml min-1. Total run time,
including equilibration, was 6 min per injection. Calibra-
tion curves, from 6.2 to 2771 ng ml-1 (0.166 to 10 mM) were
constructed as peak area ratios of derivatized 4-
hydroxycyclophosphamide (401.0→401.0, parent-to-
parent transition) and p-chlorowarfarin (341.2→160.9)
found in spiked phenylhydrazine-derivitized EDTA plasma
stock. All standards were prepared and analyzed in dupli-
cate and were back-calculated to within 15% of nominal.
Cyclophosphamide The sample processing and assay pro-
cedures for cyclophosphamide were modified from a pre-
viously published method [23]. Briefly, aliquots (100 ml) of
either EDTA plasma stock (Valley Biomedical, Winchester,
VA) spiked with cyclophosphamide for standard curves
or patient plasma had 10 ml of d4-cyclophosphamide
(0.25 mg ml-1 in methanol) added as the internal standard.
Following protein precipitation [300 ml methanol : acetoni-
trile (1:1)], 50 ml of supernatant was transferred to HPLC-
autosampler vials.
Sample analysis involved the identical instrumentation
as described above for 4-hydroxycyclophosphamide.
Tuning, operation, peak integration and data analysis were
performed in positive ion mode using multiple reaction
monitoring (Analyst software v.1.4.1, Applied Biosystems).
Reverse phase separation (aqueous phase 1 mM ammo-
nium hydroxide, pH 10, organic phase 100% acetonitrile)
was accomplished using a Synergi Fusion-RP 30 ¥ 2 mm
column with a 4 m particle size (Phenomenex, Torrence,
CA). Analysis required a 3 ml injection and a solvent flow of
0.75 ml min-1. Total run time, including equilibration, was
3 min per injection. Calibrators were prepared from a
phenylhydrazine-derivatized plasma stock containing
8313 mg ml-1 (30 mM) 4-hydroxycyclophosphamide and
cyclophosphamide concentrations ranging from 0 to
40 000 ng ml-1. A derivatized stock was used for the stan-
dard curve preparation in order to mirror the plasma
samples from patients. Calibration curves were con-
structed as peak area ratios of CTX (261.0→140.0) and
d4-CTX (265.0→144.0). All standards were prepared and
analyzed in duplicate and were back-calculated to within
15% of nominal.
Pharmacokinetic analysis
Non-compartmental pharmacokinetic analysis of cyclo-
phosphamide and 4-hydroxycyclophosphamide was con-
ducted using WinNonlin v.4.1 (Pharsight, Mountain View
CA) for AUC determination using the linear up-log down
approach. The following parameters were reported: termi-
nal elimination rate constant (lz), terminal half-life (t1/2),
maximum concentration (Cmax), time to maximum concen-
tration (tmax), AUC from time zero to infinity (AUC(0,•)),
plasma clearance (CL), volume of distribution (Vz),
estimated volume of distribution at steady-state (Vss)
and mean residence time (MRT). A bioactivation
(metabolic) ratio was calculated as the ratio of
4-hydroxycyclophosphamide AUC : cyclophosphamide
AUC.
Genotyping assessments
A 5 ml whole blood sample was collected (EDTA vacu-
tainer) and genomic DNA was isolated using a Flexigene
Qiagen kit (Qiagen, Inc., Valencia, CA, USA). Genotyping
was conducted for single nucleotide polymorphisms
(SNPs) in CYP450 genes (CYP3A4, CYP2B6, and CYP2C9) as
the proteins of these genes are relevant for metabolism of
cyclophosphamide to 4-hydroxycyclophosphamide [6–8].
Additionally, SNPs in MDR1/ABCB1, the gene responsible
for the multidrug resistance protein (P-glycoprotein) were
evaluated secondary to the role of P-glycoprotein in the
disposition of glucocorticoids and numerous chemothera-
peutic agents. Genotyping assays for CYP2B6*5 C1459T
(c30634242), CYP2B6*9 G516T (c22275631) and ABCB1/
MDR1 C1236T (c75866621) were available from Applied
Biosystems, Foster City, CA. Genotyping for ABCB1/MDR1
C3435T, CYP3A4*1b A-392G and CYP2B6*4 A785G was con-
ducted using custom assays manufactured by Applied Bio-
systems, Foster City, CA. Allelic discrimination was assessed
using 5 ml of TaqMan Universal PCR Master Mix, No AmpEr-
ase UNG(2X) (Applied Biosystems), 0.25 ml (40X assay) or
0.5 ml (20X assay), 1–20 ng genomic DNA for a reaction
volume of 10 ml. The reactions were cycled with an initial
denaturation of 95°C for 10 min followed by 50 cycles of
92°C for 15 s, and then 60°C for 1.5 min on an Applied
Biosystems 7900 Taqman PCR instrument. Prior to con-
Cyclophosphamide and 4-hydroxycyclophosphamide
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ducting the allelic discrimination reactions, a subset of
samples was sequenced using primers for the targeted
single nucleotide polymorphisms in CYP3A4*1b (A-392G)
[5-TTACATCTGTGTGAGGAGTTTGGTG-3(forward), 5-GAGT
CCAAGGGTTCTGGGTTCT-3(reverse)], CYP2B6*9 G516T [5-
CTCTCGGTCTGCCCATCTATAAAC-3(forward), 5-CTGATTCTT








TCATA-3(reverse)] from Integrated DNA Technologies, Inc.
to serve as positive controls for the allelic discrimination
assays.
Pyrosequencing assays were performed at the National
Institute of Environmental Health Sciences (NIEHS) in
Research Triangle Park, NC to determine the presence
of the CYP2C9*2 (Arg144Cys) C430T and CYP2C9*3
(Ile359Leu) A1075C alleles as described previously [24].
Pyrosequencing was performed using a PSQTM96MA
System (Biotage, Uppsala, Sweden) and allelic determina-
tion was assessed using the PMQTM96MA System Soft-
warere V.2.02.
All genotyping results were coded as 0 (wildtype/
wildtype), 1 (heterozygote) or 2 (variant/variant) for subse-
quent analyses.
Statistical analysis
Descriptive analyses (mean values and SDs) were applied
to the pharmacokinetic and laboratory parameters and
demographics. The observed genotype frequencies for
each locus were used in a chi-square test procedure for
evaluating Hardy–Weinberg equilibrium. t-tests or non-
parametric equivalent (Mann–Whitney U-test) were used
to assess for differences in demographics, laboratory
values, and pharmacokinetic parameters between SVV and
SLE groups. Relationships between continuous pharmaco-
kinetic variables for both cyclophosphamide (lz, Cmax,
AUC(0,•), CL, Vz, Vss), 4-hydroxycyclophosphamide (lz, Cmax,
AUC(0,•)), metabolic ratio, and laboratory parameters
(eCLcr, UP : Cr, serum albumin) were assessed by Spearman
rank correlation coefficients. Linear regression was applied
to significant Spearman correlations. Differences between
the pharmacokinetics by race, gender or laboratory param-
eters were assessed by Wilcoxon two sample test. In order
to explore the effects of any prescribed medications on
pharmacokinetics, mean differences in cyclophosphamide
and hydroxycyclophosphamide AUC(0,•) values were
compared between (i) prednisone-treated and untreated,
(ii) CYP2C9 inhibitor-treated and untreated and (iii)
CYP3A4 inducer-treated and untreated using t-tests or the
Mann–Whitney test, as appropriate. Differences in mean
pharmacokinetic parameters between the CYP and ABCB1/
MDR1 genotype groups (coded as 0, 1, or 2) were com-
pared using generalized linear model analyses. The
generalized linear model also controlled for race and cyclo-
phosphamide dose. P values <0.05 were considered signifi-
cant. Statistics were performed using SAS Statistical
Software, V.9.2 (SAS Institute, Inc., Cary, NC).
Results
Study population
The study consisted of SVV (n = 7) and SLE (n = 16) patients
who participated in pharmacokinetic evaluations of cyclo-
phosphamide and 4-hydroxycyclophosphamide (Table 1).
All patients had received monthly i.v. cyclophosphamide
prior to study participation. The i.v. cyclophosphamide
(Baxter Healthcare Corporation, New Providence, NJ)
dosages (mean  SD) were dependent on body surface
area: average dose 1.5  0.5 g or 0.8  0.2 g m-2 (range
0.8–2.5 g). The patients were 40  15 years of age, weighed
93  29 kg and had body surface areas of 2.0  0.3 m2. The
population included 19 females and 4 males; 74% were
non-Caucasian (15 African-American, 1 Hispanic, 1 other).
At the time of cyclophosphamide administration, the
patients had mild to moderate kidney disease: serum crea-
tinine 1.2  0.6 mg dl–1, UP : Cr of 1.4  1.8, eCLcr 94 
39 ml min-1 1.73 m–2, and serum albumin 3.5  0.7 g dl–1.
There were no significant differences noted for demo-
graphics or laboratory parameters between disease
groups, with the exception of race. Not surprisingly, more
non-Caucasian patients were found in the SLE nephritis as
compared with SVV group (95% CI 1.169, 12.205, P = 0.045).
Eighty-three percent (n = 19) of patients were receiving
chronic treatment with glucocorticoids, with a daily pred-
nisone dose of 28  20 mg (mean  SD). All patients
received a pre-cyclophosphamide anti-emetic regimen of
dexamethasone and ondansetron. Medication lists were
reviewed for potential inducers and inhibitors of CYP2B6,
CYP2C9 and CYP3A4 [25]. One patient received the
CYP2C9/CYP3A4 inhibitor amiodarone. Three additional
patients received vitamin D, which is a potential inducer of
CYP3A4 and possibly other CYPs. Two patients received
sulfamethoxazole, a CYP2C9 inhibitor. These numbers of
patients were too small to perform statistical analyses.
Pharmacokinetics of cyclophosphamide and
4-hydroxycyclophosphamide
Average i.v. cyclophosphamide doses of 0.7  0.2 g m-2
and 0.8  0.2 g m-2 were administered to SVV and SLE
patients, respectively. Plasma concentration vs. time
profiles for cyclophosphamide and 4-hydroxycyclophos-
phamide in all 23 patients are shown in Figure 1. The mean
( SD) pharmacokinetic parameters for the study popula-
tions of SVV and SLE patients are presented in Table 2. Of
note, it shows dose-normalized (to a 1 g dose) and non-
dose normalized Cmax and AUC for cyclophosphamide.
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The dose-normalized Cmax was 7793  5268 ng ml-1 for
cyclophosphamide and occurred at 1.7  1.3 h and the
dose-normalized AUC(0,•) was 74 000  26 100 ng ml-1 h.
For 4-hydroxycyclophosphamide, the Cmax was 436 
214 ng ml-1 and occurred at 2.1  2.5 h and the AUC(0,•)
was 5388  2841 ng l-1 h. The plasma CL and Vz for cyclo-
phosphamide were adjusted to a 70 kg patient to elimi-
nate differences secondary to body weight. Plasma CL of
cyclophosphamide was 12.0  4.7 l h-1 70 kg–1 and Vz was
102  33 l 70 kg–1. The t1/2 of cyclophosphamide was
6.6  3.3 h and the apparent t1/2 of hydroxycyclophospha-
mide was 8.6  5.8 h. Pharmacokinetics parameters for
cyclophosphamide and 4-hydroxycyclophosphamide
were similar between the SLE and SVV groups.
Genetic and clinical covariates and
pharmacokinetics
The frequencies of assessed genotypes (Table 3) were all in
Hardy–Weinberg equilibrium. There were no differences
found in the frequencies of any of the tested genetic vari-
ants between the SLE nephritis and SVV patient groups.
Comparisons between the mean pharmacokinetic param-
eters in the homozygous wildtype group vs. either the het-
erozygote or homozygous variant groups were assessed.
The comparisons with heterozygous vs. homozygous
variant groups were dependent on the numbers of
patients available per group. We required at least five
patients per group for any meaningful statistical analysis.
Homozygous wildtypes for CYP2B6*9 G516T had an
increased lz (0.160  0.057 h-1 vs. 0.093  0.032 h-1, 95%
CI 0.033, 0.103, P = 0.0005) for cyclophosphamide vs. vari-
ants (Figure 2A). Cyclophosphamide Vz was reduced in
homozygous wildtypes (86.9  34.0 l kg-1 vs. 118 
25.4 l kg-1, 95% CI -57.5, -4.2,P = 0.0271) (Figure 2B). Cyclo-
phosphamide dose-normalized Cmax was 1.6-fold greater
in homozygous wildtypes (9437  6864 ng ml-1 vs.
6000  1566 ng ml-1, 95% CI 696, 6179, P = 0.0176) vs. vari-
ants (Figure 2C). For the ABCB1/MDR1 C3435T polymor-
phism, there was a trend for cyclophosphamide lz to be
greater in homozygous wildtypes (0.143  0.082 h-1)
vs. variants (0.094  0.027 h-1, 95% CI –0.005, 0.102,
P = 0.0858). Additionally, a trend was demonstrated for
greater 4-hydroxycyclophosphamide Cmax in wildtypes
(511  231 ng ml-1) compared with variants (396 
201 ng ml-1, 95% CI -77.2, 308.0, P = 0.0433). When con-
trolling separately for race or cyclophosphamide dose, the
significant differences in pharmacokinetic parameters
described above based on genotype were maintained.
Additionally, homozygous wildtypes for CYP2B6*9 G516T
had reduced lzs for 4-hydroxycyclophosphamide (6.8 
1.7 h-1) as compared with variants (10.4  8.0 h-1, 95% CI
-8.3, 0.031, P = 0.0556), when controlling for dose. Graphi-
cal displays of metabolic ratios by haplotype are provided
in Figure 3. Haplotype data were not analyzed by statistics
since some haplotype groups had few patients. Due to
the low frequency of the CYP2C9 variants, pharmacokinetic
differences between CYP2C9*2 and CYP2C9*3 were not
assessed [26]. There were no differences in pharmacoki-
netic variables detected in patients according to CYP3A4
*1b and ABCB1 C1236T variant status.
Spearman correlation coefficients were used to
determine the influence of continuous clinical and
demographic covariates on cyclophosphamide and
4-hydroxycyclophosphamide pharmacokinetics. A strong
correlation was found between the apparent t1/2 of
4-hydroxycyclophosphamide and serum albumin (0.584,95%
CI 0.176, 0.820, P = 0.007). Figure 4 represents the results of
linear regression analysis of the relationship between
4-hydroxycyclophosphamide and serum albumin. Greater










Male 4 (17%) 2 (29%) 2 (13%)
Female 19 (83%) 5 (71%) 14 (87%)
Race (%)
Caucasian 6 (26%) 4 (57%) 2 (13%)
African-American 15 (65%) 1 (14%) 14 (87%)
Other 2 (9%) 2 (29%) 0 (0%)
Age (years) 40  15 47  20 36  11
Serum albumin (g dl-1) 3.5  0.7 3.6  0.8 3.4  0.7
UP : Cr 1.4  1.8 0.8  0.7 1.7  2.1
Creatinine clearance (ml min-1) 94  39 88  29 97  43
Cyclophosphamide dose (mg m-2) 0.8  0.2 0.7  0.2 0.8  0.2
Prescribed prednisone therapy (%) 19 (83%) 6 (86%) 13 (81%)
Prescribed CYP450 inducers (%) 3 (13%) 0 (0%) 3 (19%)
Prescribed CYP450 inhibitors (%) 3 (13%) 2 (29%) 1 (7%)
Data represented as mean  SD. CYP450, cytochrome P450 drug metabolizing enzyme; UP : Cr, urinary protein to creatinine excretion ratio.
Cyclophosphamide and 4-hydroxycyclophosphamide
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found in patients with serum albumin concentrations near
normal values (0.402, 95% CI –0.064, 0.724, P = 0. 079). Corre-
lations of borderline statistical significance (0.05 < P < 0.1)
were found for cyclophosphamide pharmacokinetics: lz and
serum albumin (–0.427, 95% CI –0.738, 0.034, P = 0.061), Cmax
and UP : Cr (0.367,95% CI –0.067,0.684,P = 0.085) and plasma
CL and UP : Cr (–0.392, 95% CI –0.699, 0.037, P = 0.064).These
former relationships suggest decreased cyclophosphamide
clearance and less exposure to 4-hydroxycyclophosphamide
in patients with increased urinary protein excretion. No sig-
nificant relationships between the clinical laboratory param-
eters and metabolic ratio were demonstrated. Neither
cyclophosphamide nor 4-hydroxycyclophosphamide phar-
macokinetics varied by race or gender. Similarly,no difference
in cyclophosphamide or 4-hydroxycyclophosphamide expo-
sure was found between CYP450 inducer treated and
untreated patients.The mean AUC(0,•) values for cyclophos-
phamide and 4-hydroxycyclophosphamide appeared to be
similar in prednisone treated vs. untreated patients. Statistical
comparisons were, however, limited secondary to the small
numbers of patients who did not receive prednisone (n = 4)
or who were actually receiving CYP450 inducing (n = 3) or
inhibiting (n = 3) medications.
Discussion
Cyclophosphamide in combination with glucocorticoids
has been used extensively in the treatment of glomerulo-
nephritis. Comprehensive pharmacokinetic studies are
needed to begin to guide dosing strategies for cyclophos-
phamide in glomerulonephritis secondary to SLE and/or
SVV. These studies are warranted since cyclophosphamide
metabolism to the active therapeutic moiety is compli-
cated, and alterations in serum proteins, urine protein
excretion and kidney function, all common to glomerulo-
nephritis, may alter its disposition [9, 10, 25, 27]. In this
study, we reported the pharmacokinetics of cyclophospha-
mide and 4-hydroxycyclophosphamide in 16 SLE and
seven SVV patients with kidney manifestations. The corre-
lation data for this study suggest that patients with
increased UP : Cr have increased cyclophosphamide expo-
sures (AUC(0,•) and dose-normalized Cmax, and decreased
plasma CL. Urinary protein loss may hence be a marker for
enhanced exposure to inactive cyclophosphamide as
opposed to the pharmacologically active metabolite
4-hydroxycyclophosphamide. Correlations between
increased serum albumin and increased t1/2 and AUC(0,•)
were demonstrated for 4-hydroxycyclophosphamide.
These results suggest that patients with decreased serum
albumin will have less exposure to 4-hydroxycy-
clophosphamide than patients with more physiologically
normal albumin concentrations. The data from the current
study imply that clinicians may want to consider the role of
increased urinary protein excretion and reduction in
serum albumin as factors that can limit exposure to
4-hydroxycyclophosphamide. The correlation data from
this study suggest that for every 1 g dl–1 reduction in
serum albumin, there is a decrease of 950 ng ml-1 h in
4-hydroxycyclophosphamide AUC. This could have impli-
cations for future dosing strategies based on AUC targets
that are yet to be defined.
Cyclophosphamide is only 20% bound in plasma so
variability in pharmacokinetics secondary to protein
binding (e.g. serum albumin) would not be predicted to be
relevant and this was consistent with our data [28].
However, cyclophosphamide metabolites are moderately
bound to plasma proteins (50 and 67%) and the pharma-
cokinetic disposition of total metabolite concentrations
may be influenced by alterations in plasma protein
binding through serum albumin [28, 29]. In support of this
assumption, the correlation analyses demonstrated a
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Plasma concentration (ng ml-1) vs. time (h) profile for (A) cyclophospha-
mide and (B) 4-hydroxycyclophosphamide in 23 patients with glomeru-
lonephritis secondary to lupus nephritis and small vessel vasculitis. Error
bars represent mean  SD
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decreased 4-hydroxycyclophosphamide t1/2 (P = 0.007) and
a trend towards decreased serum albumin and decreased
4-hydroxycyclophosphamide AUC(0,•) (P = 0.079). These
data suggest that decreased serum albumin may enhance
the fraction of 4-hydroxycyclophosphamide available for
further metabolism and excretion. When we evaluated
the mean 4-hydroxycyclophosphamide AUC(0,•) between
patients with reduced serum albumin (<3.5 g dl–1) and
patients with values near normal (3.5 g dl–1), the previous
assumption was supported. The 4-hydroxycyclophos-
phamide AUC(0,•) results for patients with serum albumin
<3.5 g dl–1 was 1.7-fold lower than in patients with
serum albumin 3.5 g dl–1 (3165  1787 ng ml-1 h vs.
6524  2425 ng ml-1 h; P = 0.02). The influence of alter-
ations in albumin on unbound 4-hydroxycyclophos-
phamide was not assessed.
Cyclophosphamide pharmacokinetics in glomerulone-
phritis patients resulted in higher clearance (7.5 
2.4 l h-1 m-2), lower dose normalized AUC (74 000 
26 100 ng ml-1 h) and greater Vz (1.5  0.5 l kg-1) than in
patients with cancer [30, 31]. Patients with cancer receiv-
ing cyclophosphamide doses consistent with our patients
(500–1000 mg m-2) had a t1/2 of 4.8–6.2 h, AUC 166 000–
443 000 ng ml-1 h (0.6–1.6 mmol l-1 h), CL 2.5–2.7 l h-1 m-2
and Vz 0.41–0.57 l kg-1 [30, 31]. These data suggest that
exposure to 4-hydroxycyclophosphamide may actually be
greater overall in patients with glomerulonephritis as com-
pared with patients with cancer receiving a comparable
dose. However, since 4-hydroxycyclophosphamide phar-
macokinetics are rarely reported in most cancer publica-
tions, this statement may not be applicable across all
patients.
A previous study in Caucasians with systemic vasculitis
and reduced kidney function (mean eCLcr values
78  61 ml min-1; two patients <10 ml min-1) allows
Table 2








lz (h-1) 0.13  0.06 0.13  0.05 0.13  0.06
tmax (h) 1.7  1.3 1.4  0.9 1.8  1.4
Cmax (ng ml-1) 12 210  10 300 11 670  8 650 12 400  11 200
DN Cmax (ng ml-1) 7 793  5 268 8 231  3 835 7 601  5 890
Vz (l 70 kg-1) 102  33 97  33 104  35
Vss (l 70 kg-1) 111  31 109  39 112  28
CL (l h-1 70 kg-1) 12.0  4.7 12.7  6.1 11.7  4.1
AUC(0,•) (ng ml-1 h ) 110 100  42 900 104 700  55 200 112 500  38 300
DN AUC(0,•) (ng ml-1 h ) 74 000  26 100 77 800  34 100 72 300  23 000
MRT (h) 10.2  4.3 9.3  3.2 10.6  4.8
4-hydroxycyclophosphamide
lz (h-1) 0.13  0.11 0.10  0.02 0.14  0.13
tmax (h) 2.1  2.5 3.3  4.0 1.5  1.3
Cmax (ng ml-1) 436  214 333  98 481  238
AUC(0,•) (ng ml-1 h) 5 388  2 841 4 330  2 302 5 850  2 995
MRT (h) 13.7  6.9 11.6  1.4 14.6  8.1
Metabolic ratio % 5.6  3.7 5.2  3.6 5.7  3.9
Data represented as mean  SD. AUC(0,•), area under the plasma concentration time curve from time zero to infinity; Cmax, maximum concentration in plasma; CL, systemic
clearance; DN, dose normalized to 1 g dose; MRT, mean residence time; tmax, time to maximum concentration in plasma; Vss, estimated volume of distribution at steady-state; Vz,




CYP3A4*1b A-392G (n = 46)
A 0.63
G 0.37
CYP2B6*5 C1459T (n = 46)
C 0.85
T 0.15
CYP2B6*9 G516T (n = 46)
G 0.74
T 0.26
CYP2B6*4 A785G (n = 46)
A 0.96
G 0.04
CYP2C9*2 C430T (n = 24)
C 1.0
T 0.0
CYP2C9*3 A1075C (n = 24)
A 1.0
C 0.0
ABCB1/MDR1 C1236T (n = 46)
C 0.70
T 0.30
ABCB1/MDR1 C3435T (n = 46)
C 0.63
T 0.37
CYP, cytochrome P450 gene; MDR1, multidrug resistance gene.
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comparison of cyclophosphamide pharmacokinetics with
the current study. Cyclophosphamide dose-normalized
Cmax (17.3  8.3 mg l-1 vs. 7.6  5.2 mg l-1) and dose-
normalized AUC(0,•) (154  62.7 mg l-1 h vs. 72.5 
25.6 mg l-1 h) were 2-fold higher in the previous publica-
tion [32]. Additionally, the cyclophosphamide plasma CL
values (unadjusted for weight) were 2-fold less
(120  67 ml min-1 vs. 250  77 ml min-1) in the former vs.
current study [32]. The 4-hydroxycyclophosphamide Cmax
(0.14  0.07 vs. 0.44  0.21 mg l-1) and AUC(0,•) (1.9  1.1
vs. 5.4  2.8 mg l-1 h) were 2-fold lower in the former study.
These results suggest increased formation of metabolite in
the current study. A comparison of metabolic ratios
(AUC(0,•) 4-hydroxycyclophosphamide : AUC(0,•) cyclo-
phosphamide) between studies support enhanced
metabolism of cyclophosphamide to 4-hydroxycyclo-
phosphamide in the current study (5.6  3.7% vs.
1.3  0.8%) [32]. Clinically, the two glomerulonephritis
study populations are different when considering mean
laboratory values for kidney function, serum albumin, and
urinary protein excretion. The current study included
patients with more limited perturbations in these labora-
tory parameters. The influence of kidney function on cyclo-
phosphamide pharmacokinetics were previously reported



































































































The differences in (A) cyclophosphamide elimination rate constant
(P = 0.0005), (B) volume of distribution (P = 0.0271) and (C) dose-
normalized Cmax (P = 0.0176) according to the homozygous wildtype
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Graphical displays of metabolic ratios in patients according to haplo-
types. (A) The CYP2B6*9/CYP2B6*5 haplotypes vs. corresponding meta-
bolic ratio (4-hydroxycyclophosphamide AUC : cyclophosphamide AUC)
are graphically represented. (B) The CYP2B6*9/ABCB1 C3435T haplotypes
vs. corresponding metabolic ratio are provided. For each graph,
0 = wildtype/wildtype, 1 = heterozygous, 2 = variant/variant
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10–24 ml min-1 and <10 ml min-1 who underwent dialysis
[33]. The plasma clearance of cyclophosphamide was sig-
nificantly reduced as a function of eCLcr. Reduced kidney
function as an aetiology for reduced plasma clearance
could at least partly explain differences in the plasma CL
and AUC results in the previous vasculitis study [32].
However, since only four of the patients in the current
study had eCLcr values <60 ml min-1, we could not directly
assess the role of different levels of kidney function on
cyclophosphamide pharmacokinetics.
The current study is the first to evaluate the influence
of genetic variants in drug metabolizing enzymes on
a comprehensive panel of cyclophosphamide and
4-hydroxycyclophosphamide pharmacokinetic param-
eters in patients with glomerulonephritis. Genotypes in
CYP2B6*9 G516T and ABCB1/MDR1 C3435T were found to
influence cyclophosphamide disposition. Patients with the
CYP2B6*9 G516T variant exhibited a decreased lz, higher Vz
and decreased dose-normalized Cmax for cyclophospha-
mide as opposed to patients who were homozygous wild-
type. In the present study of patients with the CYP2B6*9
G516T variant, the pharmacokinetic results demonstrate an
opposing direction of influence on Vz and lz. This would
produce the net result of an increase in t1/2 and a decrease
in cyclophosphamide CL. Patients exhibiting the ABCB1/
MDR1 variant exhibited a decrease in the lz of cyclophos-
phamide. The overall influence on systemic CL would be a
reduction, assuming that there was no change in the Vz.
These findings, while preliminary, suggest a role for
CYP2B6*9 and ABCB1 C3435T in cyclophosphamide dispo-
sition in glomerulonephritis. As elimination is comprised of
metabolism and excretion, a decreased elimination rate for
cyclophosphamide could reflect decreased metabolism to
4-hydroxycyclophosphamide. However, we did not detect
significant differences in metabolic ratio by genotype. We
did not measure urinary excretion of cyclophosphamide,
which is reportedly 20% excreted through the kidney as
unchanged drug [34]. The role of genotype, serum albumin
and urinary protein excretion on cyclophosphamide and
4-hydroxycyclophosphamide disposition requires assess-
ment of the contributing influence of each factor on phar-
macokinetics. A study design employing a larger subset of
patients exhibiting the clinical and/or genotype variables
would be needed to differentiate the role of each variable
on disposition.
In addition to the current study, previous publications
have reported on the influence of polymorphisms in
CYP450 genes on cyclophosphamide pharmacokinetics. In
patients with cancer, CYP2B6*4 A785G and CYP2B6*9 G516T
polymorphisms were reported to decrease cyclophospha-
mide CL, while the CYP2B6*5 C1459T polymorphism
reportedly increased cyclophosphamide CL [35]. Non-
significant, small effect sizes of between 3 to 9% were
reported. A recently published study reported CYP2B6
pharmacogenetics in 16 patients with SLE nephritis receiv-
ing i.v. cyclophosphamide [36]. The authors reported a
lower metabolic ratio in patients with at least one
CYP2B6*5 C1459T variant allele. Our data did not demon-
strate any relationship between the CYP2B6*5 polymor-
phism and metabolic ratio. In fact, we included a visual
check on metabolic ratio in patients with various haplo-
types of CYP2B6*9 and CYP2B6*5. Our data suggested the
highest metabolic ratio was demonstrated in patients who
were homozygous wildtype for CYP2B6*9 and homozy-
gous variant for CYP2B6*5. This would contradict the find-
ings from the previous study. Of major concern was the
unusual method for determination of metabolic ratio in
the previous study, which could have contributed to
improper conclusions. The authors obtained only one
concentration for determination of metabolic ratio instead
of comparisons of AUC. The time point (1.25 h) was below the
tmax for cyclophosphamide (1.7  1.3 h) and 4-hydroxycy-
clophosphamide (2.1  2.5 h).
It has previously been suggested that the CYP3A4 *1b
A-392G polymorphism is associated with increased cyclo-
phosphamide CL, but with a small effect size of 2% [35].
Three previous investigations also reported that
CYP2C19*2 and/or CYP2C19*3 genotypes were associated
with a reduction in the cyclophosphamide lz, decreased
bioactivation, poor kidney outcomes and a reduced risk of
premature ovarian failure [36–38]. Although hampered by
small numbers of patients, these data suggest that there
may be reductions in the extent of 4-hydroxycyclophos-
phamide formation in carriers of the CYP2C19 *2 and/or
CYP2C19*3 variants [38]. These data concerning CYP2C19
genotypes are perplexing given that CYP2B6, CYP3A4 and
CYP2C9 proteins are most contributory (45%, 25% and
12%, respectively), towards cyclophosphamide metabo-
lism to 4-hydroxycyclophosphamide as compared with
CYP2C19 protein [6–8, 39]. The CYP2B6*5/*5 genotype
(characterized by the C1459T polymorphism) has been
associated with a higher probability of reaching end-stage
renal disease in patients with lupus nephritis [38].
In conclusion, the pharmacokinetics of cyclophospha-

























Linear regression results. Linear regression of serum albumin (g dl–1) vs.
4-hydroxycyclophosphamide half-life (t1/2, h). Regression line defined as:
y = 3.566(x) - 3.593; r = 0.4007, P = 0.0799
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different in patients with glomerulonephritis as opposed
to patients with cancer. Among patients with glomerulo-
nephritis with disease secondary to SLE or SVV, the phar-
macokinetics of cyclophosphamide are similar. The present
study demonstrated that reductions in serum albumin and
increases in urinary protein excretion certainly influence
cyclophosphamide pharmacokinetic parameters, resulting
in reduced exposure to the 4-hydroxycyclophosphamide
metabolite. Patients with glomerulonephritis with the
defined genetic polymorphisms CYP2B6*9 and ABCB1
C3435T have reductions in the lz for cyclophosphamide.
The current study supports an influence of clinical covari-
ates (urinary protein excretion and serum albumin) and
genetic covariates (polymorphisms in CYP2B6 and ABCB1)
on cyclophosphamide and 4-hydroxycyclophosphamide
disposition. While the data in this manuscript provide
pharmacokinetics for cyclophosphamide and 4-hydroxy-
cyclophosphamide, additional research in terms of devel-
opment of a population PK model is needed in order to
assess adequately the dosage refinements in specific
patients and/or patient groups. Prospectively designed
studies are needed to test dosing strategies in order to
clarify the role of clinical covariates and pharmacogenom-
ics on cyclophosphamide pharmacokinetics and related
outcomes and to define pharmacokinetic targets for opti-
mizing responsiveness to glomerulonephritis treatment
regimens employing cyclophosphamide.
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